The European medical information framework: A novel ecosystem for sharing healthcare data across Europe

Simon Lovestone*, Bart Vannieuwenhuyse, Pieter-Jelle Visser, Isabelle Bos, Stephanie Vos, Johannes Streffer, Ulf Smith, Dawn Waterworth, Johan van der Lei, Peter Rijnbeek, Jose Luis Oliveira, Michel Van Speybroeck, Rudi Verbeeck, Dipak Kalra, Nathan Lea, Eva Molero, Martine Lewi, Myriam Alexander, Glen James, Caroline SageJelle Praet, Peter Egger, Gurparkash Singh, Nigel Hughes, EMIF Consortium

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Web of Science)

Abstract

Introduction The European medical information framework (EMIF) was an Innovative Medicines Initiative project jointly supported by the European Union and the European Federation of Pharmaceutical Industries and Associations, that generated a common technology and governance framework to identify, assess and (re)use healthcare data, to facilitate real-world data research. The objectives of EMIF included providing a unified platform to support a wide range of studies within two verification programmes-Alzheimer's disease (EMIF-AD), and metabolic consequences of obesity (EMIF-MET). Methods The EMIF platform was built around two main data-types: electronic health record data and research cohort data, and the platform architecture composed of a set of tools designed to enable data discovery and characterisation. This included the EMIF catalogue, which allowed users to find relevant data sources, including the data-types collected. Data harmonisation via a common data model were central to the project especially for population data sources. EMIF also developed an ethical code of practice to ensure data protection, patient confidentiality and compliance with the European Data Protection Directive, and GDPR. Results Currently 18 population-based disease agnostic and 60 cohort-based Alzheimer's data partners from across 14 countries are contained within the catalogue, and this will continue to expand. The work conducted in EMIF-AD and EMIF-MET includes standardizing cohorts, summarising baseline characteristics of patients, developing diagnostic algorithms, epidemiological studies, identifying and validating novel biomarkers and selecting potential patient samples for pharmacological intervention. Conclusions EMIF was designed to provide a sustainable model as demonstrated by the sustainability plans for EMIF-AD. Although network-wide studies using EMIF were not conducted during this project to evaluate its sustainability, learning from EMIF will be used in the follow-on IMI-2 project, European Health Data and Evidence Network (EHDEN). Furthermore, EMIF has facilitated collaborations between partners and continues to promote a wider adoption of principles, technology and architecture through some of its continued work.

Original languageEnglish
Article numbere10214
Number of pages13
JournalLearning health systems
Volume4
Issue number2
Early online date25 Dec 2019
DOIs
Publication statusPublished - Apr 2020

Keywords

  • catalogue
  • EMIF
  • EMIF-AD
  • EMIF-MET
  • use case
  • MILD COGNITIVE IMPAIRMENT
  • FATTY LIVER-DISEASE
  • TRANSLATIONAL RESEARCH
  • CLINICAL-RESEARCH
  • PREVALENCE
  • DEMENTIA
  • BIOMARKERS
  • DATABASES
  • PLATFORM
  • SUPPORT

Cite this